Login / Signup

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.

Hyun Ae JungJinyeong LimYoon-La ChoiSe-Hoon LeeJe-Gun JoungYeong Jeong JeonJae Won ChoiSumin ShinJong Ho ChoHong Kwan KimYong Soo ChoiJae Ill ZoYoung Mog ShimSehhoon ParkJong-Mu SunJin Seok AhnMyung-Ju AhnJoungho HanWoong-Yang ParkJhingook KimKeunchil Park
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The low-risk group with TRU subtype and TP53 wild-type without clinicopathologic risk factors might not need adjuvant EGFR-TKIs. In the high-risk group, with non-TRU subtype and/or TP 53 mutation, or clinicopathologic risk factors, a novel adjuvant strategy of EGFR-TKI with others, e.g., chemotherapy or antiangiogenic agents needs to be investigated. Given the poor outcome to EGFR-TKIs after recurrence in patients with the APOBEC mutation signature, an alternative adjuvant strategy might be needed.
Keyphrases